During yesterdays video, LC mentioned that she had been working on this partnership for quite some time.
My guess is that it was IMU that approached Merck/Pfizer to do the trial.
Professor Dr Ursula Wiedermann most likely has contacts in Germany / Europe.
Perhaps Dr Ursula looked at a variety of approved drugs and decided that Avelumab (BAVENCIO®) offered the best potential combination.
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-204
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
-0.002(3.39%) |
Mkt cap ! $418.9M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.2¢ | 5.7¢ | $1.588M | 26.62M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 2983283 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 916825 | 30 |
View Market Depth
| Last trade - 14.53pm 15/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |